Containing Polysaccharide (e.g., Cellulose Sugars, Etc.) Patents (Class 424/461)
-
Patent number: 8815285Abstract: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.Type: GrantFiled: March 28, 2007Date of Patent: August 26, 2014Assignee: Wockhardt Ltd.Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Saurabh Srivastava, Vinayak Dinkar Kadam, Girish Kumar Jain
-
Patent number: 8784885Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.Type: GrantFiled: July 19, 2010Date of Patent: July 22, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Yohko Akiyama, Takashi Kurasawa, Hiroto Bando, Naoki Nagahara
-
Patent number: 8784883Abstract: A capsule with good disintegration properties that can quickly display its content's efficacy as well as a method for preparing the same are provided. More specifically, provided is a capsule comprising a shell comprising low-substituted cellulose ether. Also, provided is a method for preparing a hard capsule comprising the low-substituted cellulose ether comprising a step of covering a pin for forming the hard capsule with the low-substituted cellulose ether by immersing the pin in an alkaline solution of the low-substituted cellulose ether; a step of forming the low-substituted cellulose on a surface of the pin into a gel by further immersing the covered pin in an aqueous acid solution; a step of washing by immersing the pin whose surface has been covered with the gel in water; and a step of drying.Type: GrantFiled: August 31, 2011Date of Patent: July 22, 2014Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Kazuhisa Hayakawa, Naosuke Maruyama, Miyuki Fukasawa
-
Patent number: 8765174Abstract: A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.Type: GrantFiled: December 15, 2011Date of Patent: July 1, 2014Assignee: Banner Pharmacaps Inc.Inventors: EmadEldin M. Hassan, Warren W. Kindt, Roger E. Gordon
-
Publication number: 20140178468Abstract: The present invention relates to a multiparticulate extended-release pharmaceutical composition of mesalamine comprising a) an inert core, b) an active ingredient layer and one or more pharmaceutically acceptable excipients, c) an inner coating layer comprising a water-insoluble cellulose derivative, and d) an outer coating layer comprising an enteric polymer.Type: ApplicationFiled: December 23, 2013Publication date: June 26, 2014Applicant: RANBAXY LABORATORIES LIMITEDInventors: Rajesh S. SHEAR, Abhishank SINGH, Girish MITTAL, Sumit MADAN, Vinod Kumar ARORA
-
Patent number: 8741343Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: December 2, 2010Date of Patent: June 3, 2014Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Patent number: 8722084Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.Type: GrantFiled: July 8, 2010Date of Patent: May 13, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Yohko Akiyama, Takashi Kurasawa, Hiroto Bando, Naoki Nagahara
-
Patent number: 8715728Abstract: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.Type: GrantFiled: December 3, 2009Date of Patent: May 6, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Thomas Friedl, Rolf-Stefan Brickl
-
Patent number: 8673350Abstract: The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.Type: GrantFiled: July 21, 2004Date of Patent: March 18, 2014Assignee: Capsugel Belgium NVInventors: Stephen Mark McAllister, Ronald K. Raby, Jr., Adrian Brown
-
Patent number: 8642078Abstract: A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing only tolterodine or a salt thereof and microcrystalline cellulose is described.Type: GrantFiled: March 29, 2007Date of Patent: February 4, 2014Assignee: Lek Pharmaceuticals, D.D.Inventors: Igor Legen, Polonca Kuhar
-
Patent number: 8586186Abstract: A pressure-sensitive adhesive sheet contains at least a pressure-sensitive adhesive layer containing an acrylic pressure-sensitive adhesive containing an acrylic polymer composition containing an acrylic polymer as a main component and a tackifier containing a tackifying resin as a main component, wherein reflection rate and attached amount in the fogging test in accordance with German Industrial Standard DIN 75201 are 70% or more and 2.0 mg or less, respectively. In the acrylic pressure-sensitive adhesive which forms the pressure-sensitive adhesive layer, a ratio of components having a molecular weight of 300 or less is preferably 4.2% by weight or less based on the total amount of solid matter of the acrylic pressure-sensitive adhesive. Furthermore, in the tackifying resin in the tackifier, a ratio of components having a molecular weight of 300 or less is suitably 4.2% by weight or less based on the total amount of solid matter of the tackifying resin.Type: GrantFiled: October 26, 2010Date of Patent: November 19, 2013Assignee: Nitto Denko CorporationInventors: Tomonari Naito, Michio Umeda, Akiko Takahashi
-
Patent number: 8541421Abstract: The present invention provides, in part, substituted thieno[2,3-d]pyrimidines and methods of contacting compositions with such compounds to enhance the sweet taste of said compositions.Type: GrantFiled: March 18, 2011Date of Patent: September 24, 2013Assignee: Senomyx Inc.Inventors: Catherine Tachdjian, Xiao-Qing Tang, Sara Werner, Marketa Rinnova, Qing Chen, Guy Servant, Xiaodong Li, Feng Zhang, Haitian Liu, Albert Zlotnik, Mark Zoller, Boris Klebansky, Richard Fine, Xinshan Kang
-
Patent number: 8535799Abstract: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.Type: GrantFiled: February 27, 2007Date of Patent: September 17, 2013Assignee: Veloxis Pharmaceuticals A/SInventors: Anders Burr, Michiel Ringkjøbing-Elema, Jannie Egeskov Holm, Per Holm, Birgitte Møllgaard, Kirsten Schultz
-
Patent number: 8529951Abstract: Disclosed are elastogenic cues that can be utilized to encourage growth and development of elastin-containing cellular constructs. The elastogenic cues include hyaluronan fragments and oligomers, optionally in conjunction with growth factors and/or a source of copper ions. The elastogenic cues can up-regulate elastin matrix synthesis and by vascular smooth muscle cells. In addition to encouraging synthesis of elastin in a cellular matrix and organization into elastic fibers, the elastogenic cues can also stabilize the formed ECM matrix through suppression of elastin-laminin receptor (ELR). In addition, the elastogenic cues can inhibit cell hyper-proliferation (e.g., hyperplasia) common in inflammatory vascular disease.Type: GrantFiled: February 20, 2008Date of Patent: September 10, 2013Inventors: Anand Ramamurthi, Chandrasekhar Kothapalli, Binata Joddar
-
Patent number: 8507432Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: GrantFiled: June 11, 2010Date of Patent: August 13, 2013Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stephanie Decker
-
Patent number: 8501210Abstract: The present invention has an object to provide a gel composition which has an excellent skin whitening effect and shows high storage stability even when ascorbic acid, a salt of ascorbic acid, an ascorbic acid derivative, and a salt of an ascorbic acid derivative is blended, and to provide a pack cosmetic using the gel composition. The gel composition, which comprises the following components (A)-(D): (A) a tamarind seed polysaccharide; (B) a polyhydric alcohol; (C) at least one or more of ascorbic acid, a salt of ascorbic acid, an ascorbic acid derivative, and a salt of an ascorbic acid derivative; and (D) water.Type: GrantFiled: March 6, 2007Date of Patent: August 6, 2013Assignee: The Nisshin Oillio Group, LtdInventors: Masaaki Fujisawa, Keiko Tanaka, Keiichi Oyama
-
Patent number: 8501209Abstract: The invention provides a gel-type water absorbent with rich flexibility and elasticity, with less variation in strength of gel during preservation, with low viscosity of sol, with easy processability, having a physical property with extremely less water discharge, and having functions of water absorbency and water solubility. The gel-type water absorbent contains a tamarind seed polysaccharide including 90% or more dietary fiber, 1% or less protein and 1% or less ash; and a water-soluble organic substance including at least one or more of a polyhydric alcohol and water-soluble surfactant.Type: GrantFiled: May 16, 2005Date of Patent: August 6, 2013Assignee: The Nisshin Oillio Group, LtdInventors: Yukiko Oi, Keiichi Oyama, Yuji Uzuhashi, Masaaki Kojima
-
Patent number: 8460703Abstract: A composition for the adhesive bonding and/or fixing of biological and/or synthetic tissues includes the components: a) a nitrogen-functionalized polysaccharide; and b) a terminally functionalized oligolactone.Type: GrantFiled: August 1, 2008Date of Patent: June 11, 2013Assignees: Aesculap AG, Universitat RostockInventors: Erich Odermatt, Jürgen Wegmann, Katrin Sternberg, Detlef Behrend
-
Patent number: 8367101Abstract: The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.Type: GrantFiled: January 30, 2002Date of Patent: February 5, 2013Assignee: Capsugel Belgium NVInventors: Stephen Mark McAllister, Ronald K. Raby, Jr., Adrian Brown, Allan J. Clarke, Daniel N. Margetson, Wayne Matthews
-
Publication number: 20130017259Abstract: The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and balance problems associated with Parkinson's Disease.Type: ApplicationFiled: July 3, 2012Publication date: January 17, 2013Applicant: The Parkinson's InstituteInventor: Arasteh Ari Azhir
-
Patent number: 8323691Abstract: Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer or to one or another interface of two formulation layers depending on the formulation orientation of the tablet.Type: GrantFiled: March 11, 2009Date of Patent: December 4, 2012Assignee: Alza CorporationInventors: Johan H. Geerke, Steven F. Stone
-
Publication number: 20120301542Abstract: The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 3, 2011Publication date: November 29, 2012Applicant: Pharma Two B Ltd.Inventors: Yoram Sela, Nurit Livnah, Itschak Lamensdorf, Tomer Madmon
-
Patent number: 8282955Abstract: The present invention concerns a new method of preparing granules comprising 5-aminosalicylic acid and a new method of preparing a pharmaceutical composition for the treatment of ulcerative colitis or Crohn's disease by oral administration comprising as active ingredient 5-aminosalicylic acid.Type: GrantFiled: October 11, 2002Date of Patent: October 9, 2012Assignee: Ferring B.V.Inventor: Svenn Kluver Jepsen
-
Patent number: 8236345Abstract: A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.Type: GrantFiled: July 18, 2007Date of Patent: August 7, 2012Assignee: SmithKline Beecham LimitedInventors: Karen Lewis, Nicola Jayne Lilliott, Donald Colin MacKenzie
-
Patent number: 8197850Abstract: The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine.Type: GrantFiled: November 19, 2001Date of Patent: June 12, 2012Assignee: Flamel TechnologiesInventors: Catherine Castan, Remi Meyrueix, Gerard Soula
-
Patent number: 8114444Abstract: The present invention is providing a new sustained release drug preparation comprising such and inclusion complex of a medical compound with safe botanic drug (SBD), which sustains or retards the dissolution and release of the SBD at a controlled rate from the inclusion complex and hence from the drug preparation containing the SBD, so as to maintain the concentration of the SBD in blood at an effective level for prolonged time. SBD contains Kuguasu (KU) and saponins of Kugua (SAK). SBD is very safe and it is used for treating and preventing diabetes.Type: GrantFiled: October 26, 2009Date of Patent: February 14, 2012Inventor: Yaguang Liu
-
Publication number: 20110287096Abstract: Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs.Type: ApplicationFiled: May 18, 2011Publication date: November 24, 2011Applicant: ABON PHARMACEUTICALS, LLCInventors: Sudhir GORUKANTI, Yanming Zu, Phanidhara Kotamraj, Karunakar Neelam, Salah U. Ahmed
-
Patent number: 8029821Abstract: A capsule with good disintegration properties that can quickly display its content's efficacy as well as a method for preparing the same are provided. More specifically, provided is a capsule comprising a shell comprising low-substituted cellulose ether. Also, provided is a method for preparing a hard capsule comprising the low-substituted cellulose ether comprising a step of covering a pin for forming the hard capsule with the low-substituted cellulose ether by immersing the pin in an alkaline solution of the low-substituted cellulose ether; a step of forming the low-substituted cellulose on a surface of the pin into a gel by further immersing the covered pin in an aqueous acid solution; a step of washing by immersing the pin whose surface has been covered with the gel in water; and a step of drying.Type: GrantFiled: December 20, 2004Date of Patent: October 4, 2011Assignee: Shin-Etsu Chemical Co. Ltd.Inventors: Kazuhisa Hayakawa, Naosuke Maruyama, Miyuki Fukasawa
-
Publication number: 20110189273Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: ApplicationFiled: December 2, 2010Publication date: August 4, 2011Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Patent number: 7943176Abstract: By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.Type: GrantFiled: October 8, 2002Date of Patent: May 17, 2011Assignee: Apogepha Arzneimittel GmbHInventors: Thomas Gramatte, Peter Gruber, Michael Heschel, Dirk Pamperin, Jan Ploen, Steffen Scheithauser, Wolfgang Wehner, Peter Guldner
-
Patent number: 7928111Abstract: The present invention provides compounds including substituted thienopyrimidinone derivatives of Formula (IIc) as ligands for modulating chemosensory receptors: These compounds are useful as sweet taste enhancers in comestible or medicinal compositions. The present invention also provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.Type: GrantFiled: August 8, 2007Date of Patent: April 19, 2011Assignee: Senomyx, Inc.Inventors: Catherine Tachdjian, Xiao-Qing Tang, Sara Werner, Marketa Rinnova, Qing Chen, Guy Servant, Xiaodong Li, Feng Zhang, Haitian Liu, Albert Zlotnik, Mark Zoller, Boris Klebansky, Richard Fine, Xinshan Kang
-
Publication number: 20100285120Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.Type: ApplicationFiled: July 19, 2010Publication date: November 11, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yohko Akiyama, Takashi Kurasawa, Hiroto Bando, Naoki Nagahara
-
Publication number: 20100278911Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.Type: ApplicationFiled: July 8, 2010Publication date: November 4, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yohko Akiyama, Takashi Kurasawa, Hiroto Bando, Naoki Nagahara
-
Publication number: 20100272798Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.Type: ApplicationFiled: July 8, 2010Publication date: October 28, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yohko AKIYAMA, Takashi KURASAWA, Hiroto BANDO, Naoki NAGAHARA
-
Patent number: 7803773Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: GrantFiled: September 29, 2008Date of Patent: September 28, 2010Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stefanie Decker
-
Publication number: 20100221328Abstract: Described herein are extended-release or sustained-release formulations suitable for highly soluble pharmacologically active compounds, for example, amantadine. Dosage units for providing extended release are provided by the present invention. In some embodiments, the dosage unit comprises a plurality of coated beads having drug layer and a coating layer, wherein the coating layer comprises an ethylcellulose polymer. In some embodiments, near zero-order release of the active compound is achieved.Type: ApplicationFiled: December 30, 2009Publication date: September 2, 2010Inventors: Christian F. Wertz, Victoria Ann O'Neill, Stephen M. Berge
-
Patent number: 7785853Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: June 26, 2002Date of Patent: August 31, 2010Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 7780979Abstract: This invention involves fabric-supported chitosan modified temperature responsive PNIPAAm/PU hydrogel and the use thereof in preparation of facial mask. The merit of this invention is the hydrogel formed can reversibly swell and deswell near body temperature; the incorporation of PU can suppress the syneresis of PNIPAAm at an elevated temperature; Grafting of PNIPAAm and PU onto the surface of cellulose fabrics can enhance the mechanical strength of hydrogel; Coupling of chitosan to the surface of hydrogel can not only improve the handle and skin affinity, but also render the facial mask antibacterial; The hydrogel is capable of loading a variety of nutrients (or other functional components), which can release at body temperature; the hydrogel facial mask can be reusable with repeated rinsing.Type: GrantFiled: January 27, 2006Date of Patent: August 24, 2010Assignee: The Hong Kong Polytechnic UniversityInventors: Jinlian Hu, Wenguang Liu, Baohua Liu
-
Patent number: 7767708Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.Type: GrantFiled: November 1, 1999Date of Patent: August 3, 2010Assignee: Schering-Plough Animal Health Corp.Inventors: Shih Chung, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
-
Patent number: 7759312Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.Type: GrantFiled: July 11, 2008Date of Patent: July 20, 2010Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stefanie Decker
-
Patent number: 7749537Abstract: A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.Type: GrantFiled: October 1, 2007Date of Patent: July 6, 2010Assignee: SCOLR Pharma, Inc.Inventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
-
Patent number: 7740881Abstract: Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. of from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours, and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid analgesic obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form.Type: GrantFiled: July 24, 2000Date of Patent: June 22, 2010Assignee: Purdue Pharma LPInventors: Richard Sackler, Robert Kaiko, Paul Goldenheim
-
Publication number: 20100086589Abstract: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.Type: ApplicationFiled: December 3, 2009Publication date: April 8, 2010Inventors: Thomas FRIEDL, Rolf-Stefan Brickl
-
Patent number: 7658939Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.Type: GrantFiled: November 4, 2003Date of Patent: February 9, 2010Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
-
Publication number: 20090238869Abstract: Controlled-release propranolol formulations comprise a core comprising a pharmaceutically acceptable propranolol salt and an inert core; and a coating disposed on the core, the coating comprising about 70:30 to about 85:15 of ethylcellulose:polyvinylpyrrolidone or about 60:40 to about 75:25 of ethylcellulose:hydroxypropylmethylcellulose.Type: ApplicationFiled: June 2, 2009Publication date: September 24, 2009Inventor: Grant Heinicke
-
Publication number: 20090208570Abstract: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.Type: ApplicationFiled: March 28, 2007Publication date: August 20, 2009Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Saurabh Srivastava, Vinayak Dinkar Kadam, Girish Kumar Jain
-
Patent number: 7521067Abstract: Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer or to one or another interface of two formulation layers depending on the formulation orientation of the tablet.Type: GrantFiled: June 2, 1999Date of Patent: April 21, 2009Assignee: Alza CorporationInventors: Johan H Geerke, Steven F. Stone
-
Patent number: 7510727Abstract: A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.Type: GrantFiled: December 23, 2003Date of Patent: March 31, 2009Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Mark Chasin, Hua-Pin Huang
-
Publication number: 20090053308Abstract: The present invention relates to a controlled release capsule preparation for oral administration, which contains (i) a granule containing a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof, and a hydrophilic polymer, and coated with an enteric coating agent and the like, and (ii) a fluidizer. According to the present invention, a controlled release composition for oral administration of an imidazole derivative, which has steroid C17,20-lyase inhibiting activity and which has remarkably improved sustainability of the blood concentration, is provided.Type: ApplicationFiled: March 3, 2006Publication date: February 26, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Hajime Ishida, Yukihiro Nomura
-
Patent number: RE42096Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: GrantFiled: March 24, 2005Date of Patent: February 1, 2011Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Rong-Kun Chang, Donald J. Treacy, Charlotte M. McGuiness, Edward M. Rudnic